We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Tissue Microsensor Technology Could Provide Critical Information on Clot Features in Peripheral Artery Disease

By HospiMedica International staff writers
Posted on 16 Feb 2024
Print article
Image: The smart guidewire with innovative sensors provides precise information on clot composition (Photo courtesy of Sensome)
Image: The smart guidewire with innovative sensors provides precise information on clot composition (Photo courtesy of Sensome)

Peripheral artery disease (PAD) affects over 200 million patients globally and is a significant health concern due to the systemic atherosclerotic disease it presents, especially regarding blood vessel blockages. Now, a breakthrough tissue microsensor technology could benefit millions of patients with PAD by improving long-term outcomes.

Sensome (Massy, France) has pioneered the connected medical device revolution with the world’s smallest biological tissue sensor. It has developed a breakthrough sensor technology that converts invasive medical devices into connected healthcare devices. The company’s innovative sensor technology, which combines micro-sensors based on impedance with advanced machine learning algorithms, can instantly identify various biological tissues with remarkable accuracy upon contact. Initially applied in the Clotild connected guidewire for ischemic stroke treatment, this technology was recognized as a breakthrough medical device by the FDA in 2021 for use in brain arteries.

In addition to its initial application, Sensome's technology has broader implications in fields like interventional cardiology and oncology. Currently, Sensome is undertaking the SEPARATE clinical trial, focusing on the use of the Clotild Smart Guidewire for PAD. This study aims to evaluate the sensor's effectiveness in identifying different types of blood vessel blockages in PAD patients. Specifically, the trial is centered on the sensor's ability to differentiate between soft, friable 'fresh' clots and more organized 'old' clots. Such differentiation is crucial for physicians to determine the most effective endovascular treatment strategies, ultimately reducing complications, preventing embolization, and improving the overall success of treatments.

“Understanding the makeup of a total occlusion in peripheral artery disease is essential to choose an adequate treatment approach to ensure lower complication rates and more durable long-term outcomes in this complex group of vascular patients,” said Dr. Koen Deloose, principal investigator of the SEPARATE clinical trial. “Sensome’s tissue microsensor technology could become a novel tool to characterize the total occlusion in an objective and simple-to-use way that integrates perfectly with our current existing workflow.”

“After successfully applying our technology to the treatment of ischemic stroke patients, we are excited about the opportunity to build on this work to potentially help millions of patients around the world whose lives have been impacted by PAD,” added Franz Bozsak, CEO and co-founder of Sensome.

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Ceiling-Mounted Digital Radiography System
Radiography 5000 C

Print article

Channels

Critical Care

view channel
Image: This study is significant as it addresses a treatment approach that has not been extensively studied before (Photo courtesy of 123RF)

Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease

There has been a lack of extensive research on the use of drug-coated balloon (DCB)-only strategy for the treatment of de novo left main coronary artery disease, especially in high bleeding risk (HBR) patients.... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.